The Ets Inhibitors Yk-4-279 And Tk-216 Interfere With Spib And Synergize With Lenalidomide In Diffuse Large B Cell Lymphoma Of The Activated B Cell-Like Type (Abc Dlbcl)

Background . The two main DLBCL subtypes are the germinal center B cell (GCB) and the ABC types, characterized by individual biologic and clinical features. Since up to 40% DLBCL patients are still not cured with the standard treatments there is the need of novel therapies. YK-4-279 is a small molecule that inhibits binding of the EWS1-FLI1 fusion protein to RHA resulting in growth arrest and apoptosis in Ewing sarcoma cells. Its derivative TK-216 is the first in class inhibitor of the ETS-family of transcription factors in phase I (NCT02657005 for relapsed or refractory Ewing sarcoma). Both compounds have shown promising preclinical anti-lymphoma activity. Here, we present novel data on their mechanism of action in DLBCL. Methods. Cell lines were exposed to YK-4-279 or TK-216 alone or in combination with other compounds for 72h using Tecan D300e Digital Dispenser and 96 well plates; cell proliferation was measured with MTT; synergy with Chou-Talalay combination index. Gene expression profiling (GEP) was performed with the Illumina HumanHT 12 Expression BeadChips. In vivo studies were done in NOD-SCID mice and treatments started with 60mm3 tumor volumes sc. Results. While TK-216 has shown strong in vitro and in vivo anti-lymphoma activity, only in vitro data are available for YK-4-279 in lymphomas. Here, we first confirmed the anti-tumor activity also of the latter compound in the same ABC-DLBCL model (TMD8 xenograft). Compared with control group (n=10), mice treated with YK-4-279 (100 mg/Kg, BID; n=9) clearly presented a reduction in tumor growth at D8 and D11 (P In accordance with our previous combination data showing a specific synergism of TK-216 when combined with the immunomodulatory drug (IMID) lenalidomide in ABC DLBCL, when YK-4-279 was combined with the BTK-inhibitor ibrutinib, the PI3K-delta inhibitor idelalisib, the BET inhibitor OTX-015 and lenalidomide in four DLBCL cell lines (2 ABC, 2 GCB), the biggest benefit was achieved with the combination of YK-4-279 plus lenalidomide with synergism in both ABC DLBCL. Finally, since lenalidomide is active in mantle cell lymphoma (MCL), the synergism of the combination of TK-216 and lenalidomide was confirmed also in two MCL cell lines. With the aim to understand the mechanism of action of the two small molecules, we correlated the baseline RNA expression levels of the different ETS factors with sensitivity to the drugs. SPIB was the gene presenting the most significant negative correlation with both YK-4-279 and TK-216, especially among the ABC DLBCL cell lines (P Finally, GEP of two ABC DLBCL cell lines exposed to the active (S)- or to the inactive (R)-enantiomer (500 nM, 4-8h) showed that (S)-YK-4-279 caused an important upregulation of multiple snoRNAs, an effect compatible with an interference of the compound on helicases and RNA editing. Conclusions . In ABC DLBCL, the ETS inhibitor YK-4-279 and its clinical derivative TK-216 interfere with SPIB and helicases involved in RNA editing. Moreover, both compounds act similarly to lenalidomide inhibiting IRF4 and upregulating IRF7 and synergize with the IMID in both ABC DLBCL and MCL. EC and FS equally contributed. Disclosures Zucca: Jannsen: Consultancy, Honoraria, Other: Advisory role; Jannsen: Consultancy, Honoraria, Other: Advisory role; Roche: Honoraria, Research Funding; Celltrion Healthcare: Consultancy, Other: Advisory Role; Takeda: Consultancy, Other: Advisory role; Bayer: Consultancy, Other: Advisory Role; Celltrion Healthcare: Consultancy, Other: Advisory Role; Takeda: Consultancy, Other: Advisory role; Gilead Science: Consultancy, Other: Advisory role; Gilead Science: Consultancy, Other: Advisory role; Celgene: Honoraria, Research Funding; Mundipharma: Research Funding; Mundipharma: Research Funding; Celgene: Honoraria, Research Funding; Roche: Advisory role, Honoraria, Research Funding; Sandoz: Consultancy, Other: Advisory role; Sandoz: Consultancy, Other: Advisory role; Bayer: Consultancy, Other: Advisory Role. Stathis: Roche: Consultancy, Other: Advisory board; Merck: Research Funding; Celgene: Research Funding; Pfizer: Research Funding; Amgen: Honoraria. Jessen: Oncternal Therapeutics: Employment. Lannutti: Oncternal Therapeutics: Employment. Toretsky: Oncternal Therapeutics: Membership on an entity9s Board of Directors or advisory committees. Bertoni: Menarini: Research Funding; Cellestia: Research Funding; Bayer: Research Funding; Acerta Pharma: Research Funding; Piqur: Research Funding; Immunogen: Research Funding.